Asia

Parexel, Osaka International Cancer Institute partner in Japan

Monday, August 21, 2017

Parexel International, a global biopharmaceutical services provider, and Osaka International Cancer Institute have formed an alliance to advance clinical development in Japan. The partnership will aim to drive greater efficiencies in support of patient recruitment for clinical trials in oncology and hematology, accelerating the development of innovative and effective new cancer treatments for patients.

[Read More]

Baheal Group will bring IBM’s Watson for genomics to China

Monday, June 26, 2017

IBM Watson Health announced that Baheal Pharmaceutical Group will bring Watson for Genomics to clinicians across China. As IBM’s primary channel partner for Watson for Genomics in China, Baheal will establish an ecosystem within China to sell the molecular data interpretation technology to clinicians and researchers across the country. The new multi-year agreement comes less than three months after Baheal and IBM launched a strategic alliance to distribute Watson for Oncology in China.

[Read More]

Envigo facilities in Hyderabad, India gain AAALAC accreditation

Monday, June 5, 2017

Envigo has announced that its Research Models and Services (RMS) facility in Hyderabad, India, has been granted full accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International Council. In a letter to Envigo, AAALAC notified the company that it had met all the conditions required for full accreditation and commended the high quality facility and expertise of its people.

[Read More]

Clinerion and ASUS Life partner in Taiwan

Thursday, February 16, 2017

Clinerion and ASUS Life signed a strategic alliance. Clinerion and ASUS Life, together with the Show Chwan Healthcare System, will deliver innovative services for the efficient running of clinical trials, clinical patient recruitment, market access and real-world evidence in Taiwan.

[Read More]

Eisai, Keio University to establish dementia research site

Monday, January 2, 2017

Eisai and Keio University have entered into a new joint research agreement for the discovery and development of new drugs targeting dementia. For this collaborative research, a research lab will be established, and researchers from Eisai and Keio University will work together to identify and validate novel drug targets and biomarkers that could potentially lead to the development of new therapeutics and preventive medicines for dementia.

[Read More]